For patients who do not have chronic kidney disease or cardiovascular disease but have at least three risk factors from Table 1 , SGLT-2 inhibitors decrease mortality with an NNT of 100 (95% CI, 67 to 167) over five years
The role of glutathione metabolism in chronic illness development and its potential use as a novel therapeutic target
Semaglutide is a GLP-1 receptor agonist, while Tirzepatide targets both GLP-1 and GIP pathways, offering slightly faster weight loss for some patients
Bottom line, despite what all the ads or social media influencers might tell you, GLP-1 drugs are not an easy way out
2 To our knowledge, these recommendations were not based on any headtohead randomized clinical trials or postauthorization safety studies investigating the shortterm benefit on glycemic dysregulation, kidney function, and cholesterol levels